Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2016 Oct 1;214 Suppl 2(Suppl 2):S83-92.
doi: 10.1093/infdis/jiw288.

Cardiovascular Disease, Statins, and HIV

Allison Ross Eckard  1 , Eric G Meissner  1 , Inderjit Singh  1 , Grace A McComsey  2
Affiliations
Review

Cardiovascular Disease, Statins, and HIV

Allison Ross Eckard et al. J Infect Dis. .

Erratum in

  • Erratum.
    [No authors listed] [No authors listed] J Infect Dis. 2017 Feb 1;215(3):495. doi: 10.1093/infdis/jiw583. J Infect Dis. 2017. PMID: 28362907 Free PMC article. No abstract available.
  • Erratum.
    [No authors listed] [No authors listed] J Infect Dis. 2017 Feb 1;215(3):496. doi: 10.1093/infdis/jiw627. J Infect Dis. 2017. PMID: 28362909 Free PMC article. No abstract available.

Abstract

Human immunodeficiency virus (HIV)-infected patients are at an increased risk of serious, non-AIDS-defining comorbidities, even in the setting of viral suppression with combination antiretroviral therapy. This increased risk is due in part to immune dysfunction and heightened inflammation and immune activation associated with chronic HIV infection. Statins have wide-reaching immunomodulatory effects, and their use in the HIV-infected population may be of particular benefit. In this article, we review the pathogenesis of increased inflammation during HIV infection and how it contributes to the risk of cardiovascular disease among HIV-infected individuals. We then we review the immunomodulatory effects of statins and how they may attenuate the risk of cardiovascular disease and other comorbidities in this unique patient population.

Keywords: HIV; cardiovascular disease; hydroxy-3-methylglutaryl coenzyme A reductase inhibitors; immune activation; inflammation; statins.

PubMed Disclaimer

Figures

Figure 1.
Figure 1.
Cholesterol biosynthesis pathway highlighting the biologically active metabolites and pleotropic activities. Statins have wide-reaching immunomodulatory properties that are mainly driven by inhibition of the isoprenoids geranylgeranyl pyrophosphate (GGPP) and farnesyl pyrophosphate (FPP) to perform protein prenylation (ie, isoprenylation), which is a downstream effect of inhibiting hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase in the mevalonate pathway for the synthesis of cholesterol. Abbreviation: GPP, geranyl pyrophosphate.
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. Longenecker CT, Triant VA. Initiation of antiretroviral therapy at high CD4 cell counts: does it reduce the risk of cardiovascular disease? Curr Opin HIV AIDS 2014; 9:54–62. - PMC - PubMed
    1. Group ISS, Lundgren JD, Babiker AG et al. . Initiation of Antiretroviral Therapy in Early Asymptomatic HIV Infection. N Engl J Med 2015; 373:795–807. - PMC - PubMed
    1. Ross AC, Rizk N, O'Riordan MA et al. . Relationship between inflammatory markers, endothelial activation markers, and carotid intima-media thickness in HIV-infected patients receiving antiretroviral therapy. Clin Infect Dis 2009; 49:1119–27. - PMC - PubMed
    1. Kristoffersen US, Kofoed K, Kronborg G, Giger AK, Kjaer A, Lebech AM. Reduction in circulating markers of endothelial dysfunction in HIV-infected patients during antiretroviral therapy. HIV Med 2009; 10:79–87. - PubMed
    1. Chomont N, El-Far M, Ancuta P et al. . HIV reservoir size and persistence are driven by T cell survival and homeostatic proliferation. Nat Med 2009; 15:893–900. - PMC - PubMed

MeSH terms

Substances